Oric Pharmaceuticals
ORIC
142 hedge funds and large institutions have $948M invested in Oric Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 43 increasing their positions, 51 reducing their positions, and 35 closing their positions.
10,102% more call options, than puts
Call options by funds: $10.5M | Put options by funds: $103K
140% more funds holding in top 10
Funds holding in top 10: 5 → 12 (+7)
114% more capital invested
Capital invested by funds: $442M → $948M (+$506M)
0% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 35
1% less funds holding
Funds holding: 143 → 142 (-1)
1.96% less ownership
Funds ownership: 111.52% → 109.55% (-2%)
16% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 51
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SOCM
SR One Capital Management
Wayne,
Pennsylvania
|
+$30.3M |
| 2 |
VA
VR Adviser
New York
|
+$22.9M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$19.1M |
| 4 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$12.9M |
| 5 |
NI
Nextech Invest
Zurich,
Switzerland
|
+$12.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$12.1M |
| 2 |
CC
Commodore Capital
New York
|
-$11.2M |
| 3 |
BCM
Boxer Capital Management
San Diego,
California
|
-$9.67M |
| 4 |
BlackRock
New York
|
-$9.11M |
| 5 |
State Street
Boston,
Massachusetts
|
-$3.79M |
ORIC Hedge Fund Activity: Q2 2025 in Review
142 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q2 2025, worth a combined $948M — up 114% from $442M a quarter earlier.
Fund positioning in ORIC was balanced in Q2 2025: 35 funds opened new positions, 35 closed out, 43 added to existing stakes and 51 trimmed.
The largest buyer was SR One Capital Management, opening a new position worth an estimated $30.3M. The largest seller was EcoR1 Capital, cutting an estimated $12.1M.
- 142 institutional investors held Oric Pharmaceuticals (ORIC) as of Q2 2025, down from 143 in Q1 2025.
- Funds reported $948M of Oric Pharmaceuticals stock for Q2 2025, up 114% quarter-over-quarter.
- 35 funds opened new Oric Pharmaceuticals positions in Q2 2025 and 35 closed out, a net change of 0 holders.
- The largest Oric Pharmaceuticals buyer in Q2 2025 was SR One Capital Management, an estimated $30.3M added.
- The largest Oric Pharmaceuticals seller in Q2 2025 was EcoR1 Capital, an estimated $12.1M sold.
Based on aggregated 13F filings for Q2 2025.